Tong Xiaolin

[Expert Profile] Tong Xiaolin, Chief Physician, Professor, Doctoral Supervisor, Academician of the Chinese Academy of Sciences, is an important leading figure in traditional Chinese medicine in China, working at Guang'anmen Hospital, China Academy of Chinese Medical Sciences. He has long been dedicated to clinical diagnosis, treatment, and scientific research of TCM endocrinology, diabetes and its complications, metabolic syndrome, and oncology, and is the founder of the "state-target syndrome differentiation" modern TCM diagnosis and treatment system.

[Education & Career] Professor Tong Xiaolin graduated from Nanjing College of Traditional Chinese Medicine, studied under TCM masters such as Zhou Zhongying, and has long been engaged in TCM clinical and research work. He has served as Vice President of Guang'anmen Hospital, China Academy of Chinese Medical Sciences. He was elected as an Academician of the Chinese Academy of Sciences in 2019, and has held academic positions including key discipline leader of the National Administration of Traditional Chinese Medicine. He is an important representative in the modernization research of traditional Chinese medicine in China.

[Areas of Expertise] Professor Tong specializes in TCM diagnosis and treatment of type 2 diabetes and its complications (diabetic nephropathy, peripheral neuropathy, etc.), metabolic syndrome, obesity, as well as adjuvant TCM treatment of tumors. The "state-target syndrome differentiation" theory he created combines traditional syndrome differentiation with modern disease targets. He has profound expertise in "new application of classical formulas" for metabolic diseases such as diabetes, as well as Chinese herbal hypoglycemic and lipid-lowering therapy. He excels at using high-dose classical formulas to precisely treat metabolic diseases, helping numerous diabetes patients achieve blood glucose targets and reverse complications.

[Academic Achievements & Industry Contributions] Professor Tong has led large-scale evidence-based clinical studies on TCM treatment of diabetes, with findings published in top international journals such as the Journal of the American Medical Association (JAMA), providing internationally recognized high-quality evidence for TCM treatment of diabetes. He created the "state-target syndrome differentiation" modern TCM diagnosis and treatment system, authored monographs such as Treatise on Sugar Collateral and Miscellaneous Diseases, systematically promoting the precision and standardization of TCM clinical syndrome differentiation, and led the development of multiple TCM diabetes prevention and treatment guidelines, making outstanding contributions to the inheritance, innovation, and development of traditional Chinese medicine in China.

[Clinical Practice & Outstanding Contributions] Professor Tong has long held expert TCM clinics, cumulatively treating hundreds of thousands of diabetes patients and various other patients, with significant clinical efficacy, and is praised by patients as a "hypoglycemia expert." He has repeatedly participated in TCM prevention and treatment of major infectious diseases, serving as a core member of national expert panels. He has received multiple national awards including the National Science and Technology Progress Award, trained a large number of traditional Chinese medicine leaders, and is an outstanding academic leader in the field of traditional Chinese medicine in China.

[Honors & Reputation] Professor Tong Xiaolin holds positions at Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and serves as Chair of the Diabetes Branch of the China Association of Chinese Medicine, among other academic positions. He was elected as an Academician of the Chinese Academy of Sciences in 2019, has presided over national-level major projects including the National Key R&D Program, and is an authoritative expert in the field of traditional Chinese medicine in China. The "state-target syndrome differentiation" modern TCM diagnosis and treatment system he created combines traditional syndrome differentiation with modern disease targets. He has led large-scale evidence-based research on TCM treatment of diabetes, with findings published in top international journals such as JAMA, providing internationally recognized high-quality evidence for TCM treatment of diabetes. He has actively promoted the standardization, inheritance, and innovation of traditional Chinese medicine, trained a large number of traditional Chinese medicine leaders, and is deeply trusted by patients and respected by peers alike.